Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Snehal Patel, CEO and CFO of Greenwich LifeSciences, Inc. (NASDAQ:GLSI), recently acquired 3,600 shares of the company's common stock. The transaction took place on April 7, 2025, at a price of $9.10 per share, amounting to a total purchase value of $32,760. The purchase price represents a slight discount to the current trading price of $9.59, though the stock has experienced significant volatility with a beta of 3.38 and a -41.7% return over the past year. Following this acquisition, Patel's direct ownership in the company increased to 5,561,602 shares. This move underscores Patel's continued investment in Greenwich LifeSciences, a company active in the pharmaceutical preparations sector. According to InvestingPro, the company maintains strong liquidity with a current ratio of 6.91, though it currently trades above its Fair Value. Discover more insights and 6 additional ProTips with an InvestingPro subscription.
In other recent news, Greenwich LifeSciences has reported significant progress in its Phase III clinical trial, FLAMINGO-01, which evaluates the immunotherapy GLSI-100 for preventing breast cancer recurrences. The company has observed promising preliminary safety data, with no serious adverse events reported, and the Data Safety Monitoring Board has recommended the continuation of the study without modifications. The trial has expanded its non-HLA-A02 arm to 250 patients, with approval from both EU and US regulators, potentially leading to multiple marketing approval pathways. Greenwich LifeSciences has also announced the activation of clinical sites in Germany, partnering with the German Breast Group to involve approximately 38 sites in the study. This expansion is part of the company's strategy to increase global participation, with plans to activate more sites in Europe and beyond. The trial, led by Baylor College of Medicine, is set to include up to 500 patients with the HLA-A02 allele and an additional 250 patients of other HLA types. CEO Snehal Patel highlighted the high level of interest and momentum generated by the trial, which includes participation from prominent teaching hospitals and oncology networks in the US and Europe. The company is actively developing its manufacturing and regulatory strategy for GLSI-100 in preparation for commercialization.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.